Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
- Mechanism
- Curator reviewed
Cancer-killing viruses, so-called oncolytic viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. These viruses are used, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans. This is achieved by switching off certain genes that normally enable the virus to multiply in healthy cells, which would destroy these cells. As a result of this genetic modification, the HSVs are able to reproduce in tumor cells solely, since only these offer an environment that compensates for the loss of the removed viral genes. Consequently, the virus is able to replicate in the tumor cells, selectively destroying them without harming healthy tissue.
- Primary indication
- Intended for the treatment of various forms of cancer.Curator reviewed
- Code names
- NV1020
What you can answer from here — as of October 01, 2026
Which companies are running trials of NV1020, in which indications and phases, and which of those programs are still active?